Patent analysis solutions are marketed as products and bought as capabilities, which is why product-to-product comparison tends to disappoint.
Most platforms cover several categories at once. Searching, landscaping, analytics, valuation and litigation data all appear in the same brochure, and comparing two vendors across all five produces a matrix that answers nothing.
The useful question is narrower. Which single capability solves the problem you actually have, and does this tool do that one thing well?
And a genuine possibility worth stating first: below portfolio scale, free tools cover most of it.
The four categories
| Category | Answers | Typical user |
|---|---|---|
| Search and landscaping | What exists in this technology area? | R&D, attorneys, inventors |
| Portfolio analytics | What do we hold, and what should we keep? | IP managers, in-house counsel |
| Valuation | What is this worth? | Transactions, finance, licensing |
| Litigation intelligence | Who is suing whom, over what? | Litigators, risk teams |
These need different data and different interfaces. A tool excellent at landscaping may hold no litigation data at all, and one built for portfolio administration may have weak search.
Decide your category before looking at vendors. It eliminates most of the market immediately and makes the remaining comparison tractable.
What free tools already do
| Task | Free tool | Sufficient? |
|---|---|---|
| Full-text search | Google Patents | Yes, for most searching |
| Authoritative US records | USPTO Patent Public Search | Yes |
| Families and foreign equivalents | Espacenet | Yes |
| File history and fee status | USPTO Patent Center | Yes |
| Ownership transfers | USPTO Assignment Search | Yes |
| Bulk data | USPTO Open Data, PatentsView | Yes, with technical effort |
| Landscaping at scale | — | No |
| Portfolio dashboards | — | No |
| Automated monitoring | — | No |
Data access is not what you pay for. The underlying records are public. What commercial tools sell is aggregation, workflow, monitoring and analytics on top of data anyone can get.
Which sets a clear threshold. If your need is answering specific questions about specific patents, free tools do it. If your need is watching a hundred patents continuously or mapping a whole technology area, they do not.
Landscaping: the clearest case for a tool
Mapping a whole technology area is the task free tools genuinely cannot do, and it is where the return is most visible.
| Output | Answers |
|---|---|
| Filing volume over time by assignee | Who is investing, and when they started |
| Concentration by CPC subgroup | Where the crowding is |
| White space | Subgroups with activity but few holders |
| Citation networks | Which patents the field builds on |
| Geographic filing patterns | Which markets competitors protect |
| Expiry timeline | What enters the public domain, and when |
The expiry timeline is the most actionable and least used. A map of what lapses over the next three years in your area is a map of technology becoming free to use, and almost nobody builds it.
White space analysis needs care. A subgroup with no patents may be unprotected opportunity, or it may be an area nobody patents because nothing there is patentable. The data shows the gap; it does not explain it.
Landscaping is a project, not a subscription feature. It takes a defined question, a defined technology boundary and someone to interpret the output.
The questions that separate tools
| Ask | Why it matters | A weak answer |
|---|---|---|
| What are your data sources? | Determines coverage and accuracy | Vague, or "proprietary" |
| How often does each source update? | Fee status monthly, dockets daily | One answer for everything |
| Which jurisdictions? | Rights are national | "Global" without specifics |
| Can I export? | Analysis ends up elsewhere | Restricted or premium-tier |
| Can I trace a number to its record? | Verification | Numbers with no drill-down |
| How do you handle uncertainty? | Confidence and gaps | Confident output, no error bars |
| What does the tool not do? | Honesty | "It does everything" |
The last question is the most revealing. A vendor who can describe their product's limits has thought about them. One who cannot has either not thought or will not say.
Export capability is undervalued at purchase and critical afterwards. Analysis ends up in board papers, diligence packs and spreadsheets. A tool whose output cannot leave it becomes a place data goes to be looked at rather than used.
Evaluating valuation claims specifically
This is where the most careless marketing sits, so it deserves direct questions.
| Claim | Ask |
|---|---|
| "Based on real transaction data" | Which transactions? Recorded where? |
| "Market comparables" | Comparable to what, on which attributes? |
| "AI-powered valuation" | What is the model trained on? |
| "Accurate to within X%" | Measured against what outcome? |
| "Millions of data points" | Data points are not transactions |
Modelled value estimates and transaction records are different things, and they are frequently described in the same language. Stock-market-derived value estimates, court damages awards, and recorded sale prices are three separate categories, and only the last is a price someone paid.
Ask what the number would be checked against. A valuation model has no measured accuracy unless there are outcomes to compare it to, and patent sale prices are largely private.
None of this makes estimates useless. A defensible range from disclosed inputs is genuinely valuable. It is the confident precision without a stated basis that should prompt questions.
Worked example: three needs, three answers
A solo inventor checking one idea
| Need | Is this already described? |
| Volume | One invention |
| Right answer | Google Patents, Espacenet, free |
| Then | A professional search, $500–$3,000, before filing |
| Paid platform? | No |
A subscription would sit unused. The need is a handful of searches, and free tools do them.
An in-house team with 200 patents
| Need | Renewal decisions, competitor watch, budget forecasting |
| Volume | 200 patents, three jurisdictions |
| Right answer | Portfolio analytics platform plus annuity service |
| Free tools sufficient? | No — 200 patents across three fee schedules |
| Key requirements | Export, fee calendar, entity status tracking |
The value is the calendar and the dashboard, not the data. Two hundred patents generate hundreds of deadlines across jurisdictions, and the failure mode is a missed one.
See patent portfolio management for the decision cadence a tool should support.
A litigation team assessing exposure
| Need | Who is asserting in this CPC area, and with what outcomes |
| Volume | Continuous |
| Right answer | Litigation intelligence platform |
| Free tools sufficient? | Partially — PACER exists but is slow to work with |
| Key requirements | Docket coverage, daily updates, party history |
Different category, different vendor. A landscaping tool will not hold docket data, and a portfolio tool will not either.
What tools do not decide
| Question | Tool helps? | Decides? |
|---|---|---|
| What prior art exists? | Yes | — |
| Is this claim infringed? | Charts the comparison | No |
| Should we file? | Supplies the landscape | No |
| Is this patent valid? | Surfaces references | No |
| Keep, sell or lapse? | Scores and triages | No |
| What is it worth? | Produces a range | No |
Every row where a consequence follows stays human. Retrieval and scoring scale; judgement about how an examiner, a competitor or a court will behave does not.
Which is a buying criterion in itself. A tool that presents a judgement as an output — "this patent is valid", "this product infringes" — is overstating what it can know.
Trialling properly
Most evaluations go wrong by testing the demo rather than the work.
| Do | Instead of |
|---|---|
| Run your own real question | Watching a scripted demo |
| Use patents you already know well | Unfamiliar examples |
| Check a fact you can verify independently | Trusting the dashboard |
| Export something and open it elsewhere | Assuming export works |
| Ask a question the tool should fail | Only testing strengths |
| Involve whoever will use it daily | Deciding at management level |
Test with patents you know. If you already understand a portfolio's status, term and ownership, a tool that gets those wrong tells you more in five minutes than a month of general use.
Deliberately probe a weakness. Ask for something outside its category — docket data from a landscaping tool, say. How the tool handles a question it cannot answer predicts how it will behave when you rely on it.
Where the analysis actually pays
The clearest return is at the renewal decision, because that is where money moves either way.
| Ipiry Patent Survival Curve v1.0 | Rate |
|---|---|
| Survive the 3.5-year fee (2022 cohort) | 85.8% |
| Survive the 7.5-year fee (2018 cohort) | 64.6% |
| Reach full term (2014 cohort) | 41.4% |
| Abandoned before full term | 58.6% |
| Lost at the third fee | 23.2 points |
Computed from 27,273,654 USPTO maintenance fee records covering 8,262,336 US utility patents — see the patent survival curve.
A large share of those abandonments were decided without evidence, because checking whether anyone practised the claims cost more than the fee. Analysis that makes that check cheap changes the decision directly.
Which is the honest business case for tooling. Not that it finds hidden value in every patent, but that it makes a decision you are already making three times per patent better informed.
Common buying mistakes
| Mistake | Consequence |
|---|---|
| Buying a category you do not need | Unused subscription |
| Comparing across all features | An unreadable matrix, no decision |
| Deciding from a demo | The demo is not your data |
| Ignoring export until after purchase | Analysis trapped in the platform |
| Buying to avoid a judgement | Adds cost, decides nothing |
| Not involving daily users | Adoption failure |
Deciding from a demo is the most common. Vendor demonstrations use data chosen to show the tool working, which is reasonable of them and useless to you.
Export is the requirement people discover late. It rarely appears on a feature comparison and it determines whether the tool produces work or just views.
Choosing patent analysis solutions: the checklist
- Name your category first — search, portfolio, valuation or litigation. It eliminates most of the market.
- Try the free tools properly before assuming you need a subscription. Below fifty patents they usually suffice.
- Ask what the data sources are, by name, and treat "proprietary" as an incomplete answer.
- Ask about update frequency per data type, not in general.
- Confirm jurisdiction coverage against the countries you actually hold rights in.
- Test export during a trial. Analysis has to leave the platform.
- Check you can trace any number back to its underlying record.
- Interrogate valuation claims. Modelled estimates and transaction records are not the same thing.
- Ask what the tool does not do. The answer tells you whether the vendor has thought about it.
- Do not buy software to avoid a judgement. Filing, infringement and settlement decisions need people, whatever the dashboard says.